Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’

Podobné jednotky

• Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
  Autor: Mickisch, G, a další
  Vydáno: (2010)
• Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
  Autor: Charbonneau, C, a další
  Vydáno: (2010)
• Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
  Autor: Mickisch, G H J, a další
  Vydáno: (2010)
• Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
  Autor: Mickisch, Gerald HJ, a další
  Vydáno: (2011)
• Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
  Autor: Thompson Coon, J S, a další
  Vydáno: (2009)